Tumor Biology

, Volume 37, Issue 8, pp 11259–11266 | Cite as

The conglomeration of diagnostic, prognostic and therapeutic potential of serum miR-199a and its association with clinicopathological features in epithelial ovarian cancer

  • Mariyam Zuberi
  • Imran Khan
  • Gauri Gandhi
  • P. C. Ray
  • Alpana Saxena
Original Article


Epithelial ovarian cancer (EOC) is the most lethal cause of morbidity and mortality worldwide. miRNA deregulation evinces a remarkable role in ovarian cancer tumorigenesis. miRNA-199a (miR-199a) is known to be involved in cancer development and progression. Although miR-199a has been studied in various cell types, its correlation with clinicopathological features in EOC has not been documented. In this study, we identified the clinicopathological hallmarks which might be perturbed due to the downregulation of serum miR-199a in EOC. Seventy serum samples from histopathologically confirmed EOC patients and 70 controls were collected. Total RNA from serum was isolated by Trizol method, polyadenylated and reverse transcribed into cDNA. Expression level of miR-199a was detected by using miRNA qRT-PCR. Relative expression was determined with matched controls using U6 snRNA as reference. Level of miR-199a expression was compared with distinct clinicopathological features. Expression of miR-199a was found to be significantly downregulated in comparison with matched normal controls. The expression level of miR-199a was found to be significantly associated with tumor stage, lymph node metastasis, and distal metastasis. Receiver operating characteristic (ROC) curve for diagnostic potential yielded significant area under the curve (AUC) with a considerable sensitivity and specificity. ROC curves for prognosis yielded significant AUCs for histological grade, distal metastasis, lymph node status, and survival. Our findings suggest that miR-199a downregulation might be a potential indicator for disease progression promoting the aggressive tumor progression and be identified as a diagnostic marker to predict the prognosis and survival in EOC patients.


Epithelial ovarian cancer microRNA-199a serum biomarker diagnosis prognosis 



Epithelial ovarian cancer




Quantitative real-time polymerase chain reaction



We gratefully acknowledge the assistance of University Grants Commission for supporting this work.

Compliance with Ethical Standards

Conflicts of interest


Informed consent

Written informed consent was obtained from all individual participants included in the study.

Ethical approval

All procedures performed in this study involving human participants were approved and were in accordance with the institutional ethics committee at Maulana Azad Medical College, New Delhi.


  1. 1.
    Gadducci A, Sergiampietri C, Lanfredini N, Guiggi I. Micro-RNAs and ovarian cancer: the state of art and perspectives of clinical research. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol. 2014;30(4):266–71.CrossRefGoogle Scholar
  2. 2.
    Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, et al. MicroRNA signatures in human ovarian cancer. Cancer Res. 2007;67(18):8699–707.CrossRefPubMedGoogle Scholar
  3. 3.
    Guo W, Qiu Z, Wang Z, Wang Q, Tan N, Chen T, et al. MiR-199a-5p is negatively associated with the malignancies and regulates glycolysis and lactate production by targeting hexokinase 2 in liver cancer. Hepatol Baltim Md. 2015 Jun 5.Google Scholar
  4. 4.
    Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene. 2006;25(17):2537–45.CrossRefPubMedGoogle Scholar
  5. 5.
    Ichimi T, Enokida H, Okuno Y, Kunimoto R, Chiyomaru T, Kawamoto K, et al. Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer J Int Cancer. 2009;125(2):345–52.CrossRefGoogle Scholar
  6. 6.
    Kim S, Lee UJ, Kim MN, Lee E-J, Kim JY, Lee MY, et al. MicroRNA miR-199a* regulates the MET proto-oncogene and the downstream extracellular signal-regulated kinase 2 [ERK2]. J Biol Chem. 2008;283(26):18158–66.CrossRefPubMedGoogle Scholar
  7. 7.
    Ford CE, Lau SK, Zhu CQ, Andersson T, Tsao MS, Vogel WF. Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma. Br J Cancer. 2007;96(5):808–14.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Johnson JD, Edman JC, Rutter WJ. A receptor tyrosine kinase found in breast carcinoma cells has an extracellular discoidin I-like domain. Proc Natl Acad Sci U S A. 1993;90(22):10891.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Laval S, Butler R, Shelling AN, Hanby AM, Poulsom R, Ganesan TS. Isolation and characterization of an epithelial-specific receptor tyrosine kinase from an ovarian cancer cell line. Cell Growth Differ Mol Biol J Am Assoc Cancer Res. 1994;5(11):1173–83.Google Scholar
  10. 10.
    Shen Q, Cicinnati VR, Zhang X, Iacob S, Weber F, Sotiropoulos GC, et al. Role of microRNA-199a-5p and discoidin domain receptor 1 in human hepatocellular carcinoma invasion. Mol Cancer. 2010;9:227.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Matsumura T, Sugimachi K, Iinuma H, Takahashi Y, Kurashige J, Sawada G, et al. Exosomal microRNA in serum is a novel biomarker of recurrence in human colorectal cancer. Br J Cancer. 2015 Jun 9.Google Scholar
  12. 12.
    Ge Q, Shen Y, Tian F, Lu J, Bai Y, Lu Z. Profiling circulating microRNAs in maternal serum and plasma. Mol Med Rep. 2015 Jun 3.Google Scholar
  13. 13.
    Yamada A, Horimatsu T, Okugawa Y, Nishida N, Honjo H, Ida H, et al. Serum miR-21, miR-29a and miR-125b are promising biomarkers for the early detection of colorectal neoplasia. Clin Cancer Res Off J Am Assoc Cancer Res. 2015 Jun 2.Google Scholar
  14. 14.
    Cho WC. Exploiting the therapeutic potential of microRNAs in human cancer. Expert Opin Ther Targets. 2012;16:345350.Google Scholar
  15. 15.
    Calin GA, Croce CM. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res. 2006;66:7390–4.CrossRefPubMedGoogle Scholar
  16. 16.
    Brenner B, Hoshen MB, Purim O, et al. MicroRNAs as a potential prognostic factor in gastric cancer. World J Gastroenterol. 2011;17:3976–85.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Wan D, He S, Xie B, et al. Aberrant expression of miR-199a-3p and its clinical significance in colorectal cancers. Med Oncol. 2013;30:378.CrossRefPubMedGoogle Scholar
  18. 18.
    Feber A, Xi L, Pennathur A, et al. MicroRNA prognostic signature for nodal metastases and survival in esophageal adenocarcinoma. Ann Thorac Surg. 2011;91:1523–30.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Ballabio E, Mitchell T, van Kester MS, et al. MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential. Blood. 2010;116:1105–13.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Hou J, Lin L, Zhou W, et al. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell. 2011;19:232–43.CrossRefPubMedGoogle Scholar
  21. 21.
    Henry JC, Park JK, Jiang J, et al. miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines. Biochem Biophys Res Commun. 2010;403:120–5.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Fornari F, Milazzo M, Chieco P, Negrini M, Calin GA, Grazi GL, et al. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 2010;70:5184–93.CrossRefPubMedGoogle Scholar
  23. 23.
    Duan Z, Choy E, Harmon D, et al. MicroRNA-199a-3p is downregulated in human osteosarcoma and regulates cell proliferation and migration. Mol Cancer Ther. 2011;10:1337–45.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Ichimi T, Enokida H, Okuno Y, et al. Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer. 2009;125:345–52.CrossRefPubMedGoogle Scholar
  25. 25.
    Qu Y, Huang X, Li Z, Liu J, Wu J, Chen D, et al. miR-199a-3p inhibits aurora kinase A and attenuates prostate cancer growth: new avenue for prostate cancer treatment. Am J Pathol. 2014;184:1541–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Minna E, Romeo P, De Cecco L, et al. miR-199a-3p displays tumour suppressor functions in papillary thyroid carcinoma. Oncotarget. 2014;5:2513–28.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Nam EJ, Yoon H, Kim SW, et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res. 2008;14:2690–5.CrossRefPubMedGoogle Scholar
  28. 28.
    Chen R, Alvero AB, Silasi DA, et al. Regulation of IKKbeta by miR-199a affects NF-kappaB activity in ovarian cancer cells. Oncogene. 2008;27:4712–23.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Cheng W, Liu T, Wan X, Gao Y, Wang H. MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells. FEBS J. 2012;279:2047–59.CrossRefPubMedGoogle Scholar
  30. 30.
    Joshi HP, Subramanian IV, Schnettler EK, et al. Dynamin 2 along with microRNA-199a reciprocally regulate hypoxia-inducible factors and ovarian cancer metastasis. Proc Natl Acad Sci U S A. 2014;111:5331–6.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Mariyam Zuberi
    • 1
  • Imran Khan
    • 2
  • Gauri Gandhi
    • 3
  • P. C. Ray
    • 1
  • Alpana Saxena
    • 1
  1. 1.Department of BiochemistryMaulana Azad Medical CollegeNew DelhiIndia
  2. 2.Department of SurgeryUniversity of Illinois at ChicagoChicagoUSA
  3. 3.Department of Gynaecology and ObstetricsLok Nayak HospitalNew DelhiIndia

Personalised recommendations